Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin.
Level 5 - mechanism / opinion, no new human data
Preclinical cell culture and animal experimental study with no human data
PubMed 19605645 · doi:10.1523/JNEUROSCI.1071-09.2009
What was done
The study examined the pathway by which beta-amyloid (Abeta) oligomers induce c-Jun N-terminal kinase (JNK) activation, leading to phosphorylation/degradation of insulin receptor substrate-1 (IRS-1) and phosphorylation of tau. Experiments were conducted in cultured hippocampal neurons treated with Abeta oligomers, JNK inhibitors, or docosahexaenoic acid (DHA). In vivo, 3xTg-AD transgenic mice were fed a diet high in saturated and omega-6 fat and treated with fish oil, curcumin, or a combination of both for 1 or 4 months, evaluating biochemical markers (JNK, IRS-1, tau) and spatial working memory via the Y-maze.
What was found
The abstract reports directional findings without numerical values, confidence intervals, or exact p-values. In cultured hippocampal neurons, Abeta oligomers increased active JNK and phosphorylation of IRS-1 (Ser616) and tau (Ser422); these effects were blocked by JNK inhibition or DHA. In 3xTg-AD mice on a high-fat diet, treatment with fish oil, curcumin, or their combination for 4 months decreased phosphorylated JNK, IRS-1, and tau, preserved total IRS-1 protein, and improved Y-maze performance. A 1-month combination regimen produced stronger inhibition of phosphorylation and greater Y-maze improvement than monotherapy.
Why it matters
The findings delineate a mechanistic link between amyloid pathology, tau phosphorylation, and neuronal insulin resistance via JNK signaling. They suggest that dietary components such as omega-3 fatty acids and curcumin can modulate these neurodegenerative signaling pathways in preclinical models.
Limits
The study is restricted to cell culture and a transgenic mouse model, precluding direct clinical translation to human Alzheimer's disease. The abstract omits sample sizes (n), quantitative effect sizes, baseline comparator values, and statistical measures. Bioavailability, optimal human dosing, and potential adverse effects of high-dose supplementation were not addressed.
Cited by
- supports Amyloid-beta disrupts insulin signaling by interfering with the insulin receptor and its substrate IRS-1.